BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $73.20 Million Stock Holdings in Medtronic plc (NYSE:MDT)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Medtronic plc (NYSE:MDT) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 813,041 shares of the medical technology company’s stock after purchasing an additional 22,232 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.06% of Medtronic worth $73,198,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Pzena Investment Management LLC increased its holdings in Medtronic by 3.3% in the 3rd quarter. Pzena Investment Management LLC now owns 8,582,993 shares of the medical technology company’s stock valued at $772,727,000 after buying an additional 275,870 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Medtronic by 7.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 7,120,554 shares of the medical technology company’s stock worth $560,494,000 after acquiring an additional 515,751 shares in the last quarter. Raymond James & Associates increased its stake in Medtronic by 2.3% in the third quarter. Raymond James & Associates now owns 6,391,865 shares of the medical technology company’s stock valued at $575,460,000 after acquiring an additional 145,504 shares during the last quarter. 1832 Asset Management L.P. raised its position in Medtronic by 26.9% during the second quarter. 1832 Asset Management L.P. now owns 4,915,609 shares of the medical technology company’s stock valued at $386,908,000 after purchasing an additional 1,041,863 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in Medtronic by 0.8% during the second quarter. Bank of Montreal Can now owns 2,756,336 shares of the medical technology company’s stock worth $234,068,000 after purchasing an additional 22,240 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MDT. Sanford C. Bernstein boosted their price target on Medtronic from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research report on Monday. UBS Group raised shares of Medtronic from a “sell” rating to a “neutral” rating and increased their target price for the stock from $76.00 to $90.00 in a report on Thursday, August 15th. JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $99.00 to $96.00 and set a “neutral” rating on the stock in a report on Friday, November 15th. Finally, Truist Financial increased their price objective on shares of Medtronic from $90.00 to $93.00 and gave the company a “hold” rating in a research note on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $95.19.

Medtronic Trading Up 0.7 %

NYSE MDT opened at $84.71 on Friday. The firm has a market capitalization of $108.63 billion, a PE ratio of 25.90, a price-to-earnings-growth ratio of 2.42 and a beta of 0.84. The business’s 50-day moving average price is $89.07 and its two-hundred day moving average price is $84.84. The company has a current ratio of 1.84, a quick ratio of 1.61 and a debt-to-equity ratio of 0.51. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $92.68.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The business had revenue of $8.40 billion for the quarter, compared to analysts’ expectations of $8.27 billion. During the same period in the prior year, the business posted $1.25 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. On average, analysts expect that Medtronic plc will post 5.46 EPS for the current year.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.